A Strategic Analysis of Novartis

1722 Words4 Pages

The original case was about Chiron, a biotechnology company, in the United States. Chiron was acquired in 2006 by Novartis, a Swedish company formed by the merger of Ciba-Geigy and Sandoz Laborites. Since Chiron itself no longer exists, we have focused our case around Novartis as of 2013. Novartis specializes in diagnostic services, generic and name brand medications, ophthalmological tools, as well as a small segment in pet health. The business prides itself in producing the latest drugs, hiring the best talent, and being a global leader in the pharmaceutical industry. Over the years the company has survived by focusing on its internal development in addition to a series of mergers, acquisitions, and corporate restructurings. Being a pharmaceutical company, the entire population is impacted: patients, physicians, employees, hospitals, and investors are some of the most important stakeholders. We first began our analysis of Novartis by evaluating the company’s strategic direction. Novartis’ mission statement is to care and to cure. They are a company that wants to discover, develop, and successfully market innovative products to prevent and cure disease, to ease suffering, and to enhance the quality of life. Novartis also hopes to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest their money, their time, and their ideas in their company. Like most companies in the industry, Novartis’ vision is to become the best pharmaceutical company through the achievement of sustainable and profitable growth. Novartis has a performance oriented culture and top down leadership style. By having a performance oriented culture the business pushes creativity and free thinking while focusing ... ... middle of paper ... ...including their expiring patents and inefficiencies in their research and development practices. In the end, Novartis has a very strong internal environment. Their strategic direction, value chain, strengths, resources, and capabilities have allowed them to grow, develop, and truly become a global leader in the pharmaceutical industry. Novartis is currently one of the largest companies in the pharmaceutical industry, for both generic and brand name medication. One of components that led to Novartis becoming such a large company is their presence in a worldwide geographic market. Novartis is currently in the growth phase of the industry life cycle, and it is expected to be there for the foreseeable future. Novartis will continue to be a threat to its rivals in the industry, which include companies such as Johnson and Johnson, Pfizer, Merck, and Bristol-Myers Squibb.

Show More
Related

  • Breathe Right Strips

    974 Words  | 2 Pages

    The CNS Company is already a successful company due to the achievements of its breathing right strips. In my analysis we learned that they already do a lot of things right. What they need to be aware of is the different economical situations in the global marketplace, there are different ways that the product is approved abroad, and there is competition lurking. CNS needs to continue to leverage their strengths, but capitalize on their opportunities and benchmark the competition.

    Read More

  • Davita Case Study

    1443 Words  | 3 Pages

    In 2014 DaVita’s return on investment (ROI) ranked third highest in the industry (“DaVita 's ROI”, n.d.). The organization reported an average ROI of 4.96%, ROI has increased since 2012 (“DaVita 's ROI”, n.d.). Market share is a way to evaluate the portion of an industry held by an organization, a measure of performance relative to the competition (“Market share”, n.d.). In 2014 DaVita held a third of the global market share while their biggest competitor, Fresenius, had a five percent lead in market share. Experts believe DaVita has no reason to worry their shares “over the past year, DaVita has a 10% lead on Fresenius and that lead only increases at the two-year (roughly 60%), and five-year

    Read More

  • Business Strategies Used by CVS Company

    1364 Words  | 3 Pages

    ...ll help the company in selling generic drugs and provide affordable medications to its customer base.

    Read More

  • The Great Gatsby American Dream Failure

    810 Words  | 2 Pages

    Many businesses that achieve great success become greedy and want more. Pharmaceutical companies, such as Turing, have been overpricing life-saving drugs since they’ve been discovered. Martin Shkreli, the CEO of the company that raised the price of the H.I.V medicine, was arrested because of wrongdoings involving his former hedge fund and a pharmaceutical company he previously headed. He has been charged with conspiracy to commit security fraud, wire fraud, and using his previous company to cover personal debts. U.S. Attorney Robert Capers says, “As alleged in the indictment, Shkreli essentially ran his companies like a Ponzi scheme, where he used each subsequent company to pay off the defrauded investors in the prior company” (Shkreli).

    Read More

  • The Merger of Two Competing Hospitals: A Case Study

    3362 Words  | 7 Pages

    A merger is a partial or total combination of two separate business firms and forming of a new one. There are predominantly two kinds of mergers: partial and complete. Partial merger usually involves the combination of joint ventures and inter-corporate stock purchases. Complete mergers are results in blending of identities and the creation of a single succeeding firm. (Hicks, 2012, p 491). Mergers in the healthcare sector, particularly horizontal hospital mergers wherein two or more hospitals merge into a single corporation, are increasing both in frequency and importance. (Gaughan, 2002). This paper is an attempt to study the impact of the merger of two competing healthcare organization and will also attempt to propose appropriate clinical and managerial interventions.

    Read More

  • Novaris Pharmaceuticals Case Study

    738 Words  | 2 Pages

    Being presented with the problems in the implementation of the SAP ERP system, it is evident that Novartis Pharmaceuticals requires a comprehensive action plan that resolves key issues and the underlying problem. Refer to Exhibit A for a graphical representation of the action plan.

    Read More

  • Merck & Company

    874 Words  | 2 Pages

    Main Issue In 2000, Rich Kender, Vice President of Financial Evaluation and Analysis at Merck & Company was discussing the opportunity of investing in licensing, manufacturing and marketing of Davanrik, a drug originally developed to treat depression by LAB Pharmaceuticals. LAB proposed to sell the rights of all the future profits made from the successful launch of Davanrik at the cost of an initial fee, royalty payments and additional payments as the drug completed each stage of the approval process. Merck & Company's organizational goal is to constantly refresh its drug development portfolio and reach as many customers as possible during the patented period. So there was not only the potential of financial gain or quantitative aspect of the offer, but also the qualitative value which will be added by getting better positioning in the risky pharmaceutical industry.

    Read More

  • Eli Lilly And Company: The Global Pharmaceutical Company

    1326 Words  | 3 Pages

    Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.

    Read More

  • The Power and Benefits of Monopolies in the Pharmaceutical Industry

    1993 Words  | 4 Pages

    Although monopolies appear damaging at times, there are arguments that they are an advantage to society. Monopolies in the pharmaceutical industry drive companies to pursue research and development (R&D) efforts to gain new patents. According to a 1992 study, among the 24 US. Industry groups, pharmaceuticals dedicated 16.6% of their amounts to basic research, while all other industries averaged at 5.3% (Sherer 1307). This fact validates the incentive pharmaceutical companies have to get a patent and acquire more power. Pfizer encourages R&D because of the incentives and a want to obtain patents to receive more profit. Pfizer has to promote itself to be successful, creating a good brand image that consumers will trust. If the company can advertise successfully, more consumers will purc...

    Read More

  • CEMEX Expansion Strategy

    2249 Words  | 5 Pages

    It is as a result of acquiring distinct competitive advantages that CEMEX was able ...

    Read More

  • Business Analysis: Merck & Co.

    1393 Words  | 3 Pages

    10. Collis, David, and Troy Smith. "Strategy in the Twenty-First Century Pharmaceutical Industry:Merck&Co. and Pfizer Inc." Harvard Business School, 2007: 8-12.

    Read More

  • Eli Lilly and Company Case Analysis

    1605 Words  | 4 Pages

    In choosing to narrow its focus on its core pharma business in the 1990s, Lilly appears to have either deliberately or inadvertently made a choice to funnel their efforts into the category of neuroscience with the patented products Prozac and Zyprexa, Lilly's top sellers. Its imbalanced portfolio and lagging international sales was the consequence of its dependence on just a few key products. This type of a strategy with a focus on neuroscience was not well suited to the more cost conscious international regions whose focus was treatment of disease. Other factors that played against them were the regulations in non-US developed countries on pricing and payment programs for pharmaceutical drugs through national health insurance programs. Due to this fact, Lilly wouldn't have earned as high of a profit margin on its blockbuster drugs, Prozac and Zyprexa, in Europe and Japan as ...

    Read More

  • Johnson And Johnson: The Competitive Environment Of Johnson & Johnson

    1604 Words  | 4 Pages

    The company shows a flat organization in which there are few layers of management but has broad span of control. According to the chart, the company develops a decentralized authority in the level of their management due to which they focus more on adapting to what customer wants based on decision making from the lower level managers who are more familiar in the local conditions. This type of authority allows them to understand customers such as patients’ needs in order to develop strategies to fulfill this requirement According to Figure 1, they primarily focus more on the health care system and invested in about $7.5 billion dollars in research and development to create a strong product portfolio. The culture of this organization demonstrates a formal organization in order to guide the lines of authority as well as the responsibility for the company. According to Johnson and Johnson Credo statement, their main focus is towards the responsibilities of the doctors, nurses, and patients as well as their employees. They also state their growing responsibilities toward the shareholders and to the communities in order to research and develop new innovations in towards civic improvement to the communities. This entails that they fully care for their customers and employees in which its shows in

    Read More

  • Business Analysis of Teva Pharmaceuticals

    2720 Words  | 6 Pages

    Many new players entered the market copying the same techniques for growth as Teva to capture a significant market share by offering low prices due to their low cost strategies. The entry of these players made the industry intense with tough competition, low profit margins and collapsed prices. The segment of drug industry where Teva had to come up with innovative drugs demands to invest high capital on R&D that was in billions for a single drug could potentially lower the growth and revenues for Teva and could push the company into serious trouble. Analysis To build some effective and real world alternatives and recommendations to Teva Pharmaceuticals, we will conduct the following analysis to understand the external and internal situation of the company. Internal and External Analysis SWOT Analysis (Exhibit 1) Strengths:

    Read More

  • An Analysis of Johnson & Johnson

    2815 Words  | 6 Pages

    ... global marketplace, it is also essential that Johnson & Johnson focuses on the critical drivers of their future growth: to create value through innovation, to extend their global reach, with local focus, to execute with excellence in everything it does and to inspire leadership with purpose among the people who carry on the Johnson & Johnson legacy.

    Read More

More about A Strategic Analysis of Novartis

Open Document